Long noncoding RNA are aberrantly expressed in human papillary thyroid carcinoma

Abstract

Long noncoding RNAs (lncRNAs) have emerged as key regulatory molecules at almost every level of gene expression regulation. The altered expression of lncRNAs is a characteristic of numerous types of cancer, and lncRNAs have been demonstrated to promote the development, invasion and metastasis of tumors through various mechanisms. However, the role of lncRNAs in papillary thyroid carcinoma (PTC) remain unclear. In the present study, differentially expressed lncRNAs and mRNAs were detected by human lncRNA microarray in three pairs of PTC and adjacent noncancerous samples. The microarray results revealed that 675 lncRNAs and 751 mRNAs were abnormally expressed in the three PTC samples compared with adjacent noncancerous samples (fold change ≥2.0; P<0.05). To validate the microarray results, 8 differentially expressed lncRNAs were randomly selected for quantitative polymerase chain reaction (qPCR). The results of qPCR were consistent with the microarray data; the 8 lncRNAs had an aberrant expression in the PTC samples compared with the adjacent noncancerous samples. Gene ontology and pathway analysis indicated that there were 7 downregulated pathways and 29 upregulated pathways in PTC. LncRNA classification and subgroup analysis revealed 7 pairs of enhancer-like lncRNA-mRNA, 9 pairs of antisense lncRNA-mRNA and 45 pairs of lncRNA-mRNA were differentially expressed between PTC and their paired noncancerous samples. In conclusion, the present study identified a series of novel PTC-associated lncRNAs. Further study with these lncRNAs is instrumental for the identification of novel target molecules that could lead to improved diagnosis and treatment for PTC.

Integrative Analysis of Methylation and Transcriptome Identified Epigenetically Regulated lncRNAs With Prognostic Relevance for Thyroid Cancer

“…Numerous studies have demonstrated the superiority of lncRNA as diagnostic and predictive biomarkers in a diverse range of cancers compared to mRNAs and miRNAs (Zhou et al, 2015c(Zhou et al, , 2017(Zhou et al, , 2019Zhou M. et al, 2018b). Aberrant lncRNA expression has also been observed in the development and progression of THCA (Yang et al, 2016;Lu et al, 2018), and several lncRNA biomarkers have been identified for THCA diagnosis and prognosis (Li et al, 2017;Liu et al, 2018;Liang and Sun, 2019). Emerging evidence has shown that DNA methylation is an important epigenetic regulator of lncRNA expression and epigenetic changes in DNA methylation can disturb the expression pattern of lncRNAs and contributes to carcinogenesis (Heilmann et al, 2017;Tang, 2018;Zhou Z. et al, 2018;Bao et al, 2019).…”

Identification of novel long non-coding RNA biomarkers for prognosis prediction of papillary thyroid cancer

“…Like proteins, mRNAs and miRNAs, lncRNAs are emerging as novel molecular biomarkers for early diagnosis and prognosis prediction in various cancers [ 12 – 20 ]. Most recently, thousands of lncRNAs were found to be differentially expressed between PTC and adjacent noncancerous samples [ 21 ]. Another study performed by Lan et al .…”

Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases

“…P value of TCONS_00024700, NR_028494, ENST00000462717 and ENST00000415582 was < 0.001, <0.001, <0.001 and 0.035,respectively. lncRNAs respectively, which lay the foundation for further investigation of lncRNAs related to PTC [26,27]. In addition, important regulatory mechanisms of lncRNAs in the process of tumorigenesis, progression, proliferation, metastases, apoptosis and autophagy of PTC have been reported [27][28][29][30][31][32].…”